LAWRENCEVILLE, N.J. , March 15, 2023 (GLOBE NEWSWIRE) -- I MUNON , Inc. (NASDAQ: IMNN ) , a clinical-stage drug development company, today announced that an abstract related to the Company’s DNA-based immunotherapy has been accepted for presentation at the American Association for Cancer Research
Reviews 2022 accomplishments; sets forth 2023 milestones and long-term vision LAWRENCEVILLE, N.J. , March 01, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) , a clinical-stage biotechnology company, today announced that Dr. Corinne Le Goff , the company’s president and chief executive
The study will be partially funded by Break Through Cancer through the Ovarian Minimal Residual Disease Team Lab LAWRENCEVILLE, NJ and CAMBRIDGE, MA , Feb. 27, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN ) , a clinical-stage biotechnology company, and Break Through Cancer, a public
Non-dilutive funding strengthens balance sheet and extends current operating runway into 2025 The sale of an additional $1.8 million of unused New Jersey NOLs expected in 2023 LAWRENCEVILLE, NJ , Jan. 12, 2023 (GLOBE NEWSWIRE) -- I MUNON , Inc. (NASDAQ: IMNN ) , a clinical-stage drug development
LAWRENCEVILLE, NJ and PHILADELPHIA, PA , Jan. 05, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN ) , a clinical-stage drug development company, and The Wistar Institute , a global leader in biomedical research located in the heart of University City, Philadelphia , through its Vaccine &
